Jan 27 (Reuters) - Veru ( VERU ) said on Monday its

experimental drug, in combination with Novo Nordisk's

weight-loss treatment Wegovy, helped preserve muscle in older

patients with obesity, meeting the main goal of a mid-stage

study.

The study was testing Veru's ( VERU ) oral drug, enobosarm, in

patients aged 60 and above. The drug targets androgen hormones,

which play a role in body development and reproductive health.

Patients who received the drug in combination with

Wegovy lost 71% less lean muscle on average than those who

received Wegovy alone, the company said.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Arun

Koyyur and Devika Syamnath)